Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX) has been given a consensus recommendation of “Buy” by the eighteen ratings firms that are currently covering the company, Analyst Ratings.Net reports. One research analyst has rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $145.02.

A number of analysts have recently weighed in on VRX shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday. They now have a $153.00 price target on the stock.

In other Valeant Pharmaceuticals Intl news, EVP Robert Roswell Chai-Onn sold 10,000 shares of the stock on the open market in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $130.08, for a total transaction of $1,300,800.00. Following the sale, the executive vice president now directly owns 23,999 shares of the company’s stock, valued at approximately $3,121,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.60% during mid-day trading on Friday, hitting $122.05. 938,653 shares of the company’s stock traded hands. Valeant Pharmaceuticals Intl has a one year low of $73.25 and a one year high of $153.10. The stock’s 50-day moving average is $128.9 and its 200-day moving average is $125.. The company’s market cap is $40.919 billion. Valeant Pharmaceuticals Intl also saw a large increase in short interest in April. As of April 30th, there was short interest totalling 10,358,313 shares, an increase of 166.3% from the April 15th total of 3,889,779 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,674,623 shares, the short-interest ratio is presently 2.2 days.

Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Thursday, May 8th. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.